Antidiabetic Melanotan 2 99% 910463-68-2 API Powder Semaglutide

• Function: Specialist Drugs, Antidiabetic Medication
• Certification: GMP
• Grade Standard: Medicine Grade
• Type: API Raw Materials
• State: Powder
• C187h291n45o59: C187h291n45o59
• Model NO.: 910463-68-2
• Transport Package: Box, Bags
• Specification: 25kg/50kg/100kg
• Trademark: ECHEMI
• Origin: China
• HS Code: 30049099

Product Description

CAS NO:	910463-68-2
Product Name:	Semaglutide
Molecular Formula:	C187H291N45O59
Formula Weight:	4113.57754
Appearance:	Solid powder
Purity:	>98%
Storage:	Dry, dark, and at 0 - 4 C for the short term (days to weeks) or -20 C for the long term (months to years).
Solubility:	Soluble in DMS
Shipping Condition:	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

WHAT IS SEMAGLUTIDE AND HOW DOES IT WORK?

Semaglutide is a prescription medication used to treat Type 2 Diabetes Mellitus and for Weight Management

WHAT ARE DOSAGES OF SEMAGLUTIDE?

Adult dosage

Injection, prefilled, single-dose pen 

• 2mg/1.5mL (1.34mg/mL); delivers doses of 0.25mg, 0.5mg, or 1mg per injection
• 4mg/3mL (1.34mg/mL); delivers 1 mg per injection

Injection, prefilled, single-dose pen 

• 0.25mg/0.5mL
• 0.5mg/0.5mL
• 1mg/0.5mL
• 1.7mg/0.75mL
• 2.4mg/0.75mL

Oral tablet 

• 3mg
• 7mg
• 14mg

Type 2 Diabetes Mellitus

Adult dosage

SC

• 0.25 mg SC once per week for 4 weeks initially; then increase to 0.5 mg per week
• If glycemic control is not achieved after at least 4 weeks on a 0.5-mg dose, can increase to 1 mg once weekly
• Note: the initial 0.25-mg dose is intended for treatment initiation and is not effective for glycemic control

Oral

• Initial: 3 mg orally once daily for 30 days; then the 3-mg dose is intended for treatment initiation and is not effective for glycemic control
• After 30 days on 3 mg/day: increase to 7 mg orally once daily
• After 30 days on 7 mg/day: may increase the dose to 14 mg orally once daily if additional glycemic control needed
• Note: Taking two 7-mg tablets to achieve a 14 mg dose is not recommended

Switching between Semaglutide (SC) and Ryhelsus (orally)

• Taking 14 mg/day orally: Transition to 0.5 mg SC once weekly on the day after the last oral dose
• Taking 0.5 mg/week SC: Transition to 7 mg or 14 mg orally starting up to 7 days after last SC injection
• There is no equivalent oral dose for the 1-mg SC dose

Weight Management

Adult dosage

• Initiate with a low dose and gradually escalate to a maintenance dose of 2.4 mg/week SC to minimize GI adverse reactions
• If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decrease to 1.7 mg once weekly, for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once-weekly; discontinue if not tolerated after the second attempt 
• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1 mg
• Weeks 13-16: 1.7 mg
• Week 17 onward: 2.4 mg (maintenance)